USPTO issues patent to SANUWAVE's new method that produces acoustic shock waves

SANUWAVE Health, Inc. (OTCBB: SNWV) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 8,092,401, titled "Method and Apparatus for Producing Shock Waves for Medical Applications." The patent has a term extending to February 2027 and relates to a new method of producing shock waves utilizing a mechanically pressurized fluid.

In conventional methods to produce an acoustic shock wave, the acoustic wave is triggered by an electrical impulse. By contrast, the novel method presented in this patent is mechanical and comprises oscillating high pressure generated in the encapsulated fluid within the treatment applicator, which is used to produce focused acoustic shock waves. This innovation may create efficiencies in design, manufacture and usability of the Company's Pulsed Acoustic Cellular Expression (PACE®) technology and allows for unique device configurations and clinical applications that were not previously possible.

"We are pleased to be awarded this new patent as it has potential to be a significant asset in our product development efforts," stated Christopher M. Cashman, President and CEO of SANUWAVE. "This method of producing acoustic shock waves is different from the electrohydraulic method we use in our current products, and it could give rise to new clinical indications and alternative regulatory pathways for future product offerings."

Source: SANUWAVE Health, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.